The price of Gilead Sciences Inc. (NASDAQ:GILD) shares last traded on Wall Street fell -0.08% to $78.32.
GILD stock price is now -3.51% away from the 50-day moving average and 1.41% away from the 200-day moving average. The market capitalization of the company currently stands at $98.36B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
With the price target enhanced from $90 to $100, BMO Capital Markets Upgraded its rating from Market Perform to Outperform for Gilead Sciences Inc. (NASDAQ: GILD)., while ‘RBC Capital Mkts’ rates the stock as ‘Sector Perform’.
In other news, Parsey Merdad, Chief Medical Officer sold 6,126 shares of the company’s stock on Mar 13. The stock was sold for $483,893 at an average price of $78.99. Upon completion of the transaction, the Chief Medical Officer now directly owns 70,130 shares in the company, valued at $5.49 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, Chief Medical Officer Parsey Merdad sold 12,984 shares of the business’s stock. A total of $1,038,225 was realized by selling the stock at an average price of $79.96. This leaves the insider owning 70,130 shares of the company worth $5.49 million. Insiders disposed of 205,591 shares of company stock worth roughly $16.1 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GILD stock. A new stake in Gilead Sciences Inc. shares was purchased by FARMER STEVEN PATRICK during the first quarter worth $102,577,000. VIRGINIA RETIREMENT SYSTEM invested $53,265,000 in shares of GILD during the first quarter. In the first quarter, JUPITER ASSET MANAGEMENT LTD acquired a new stake in Gilead Sciences Inc. valued at approximately $28,113,000. OFI INVEST ASSET MANAGEMENT acquired a new stake in GILD for approximately $18,266,000. QUBE RESEARCH & TECHNOLOGIES LTD purchased a new stake in GILD valued at around $16,959,000 in the second quarter. In total, there are 2,365 active investors with 83.00% ownership of the company’s stock.
During the past 12 months, Gilead Sciences Inc. has had a low of $57.17 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.20, a current ratio of 1.30, and a quick ratio of 1.10. According to the stock market information, the enterprise value for the company is $117.36B, which is based on a 17.70 price-to-earnings ratio, a 7.87 price-to-earnings-growth ratio, and a beta of 0.41. The fifty day moving average price for GILD is $81.11 and a two-hundred day moving average price translates $77.33 for the stock.
The latest earnings results from Gilead Sciences Inc. (NASDAQ: GILD) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.37, missing analysts’ expectations of $1.54 by -0.17. This compares to $0.01 EPS in the same period last year. The net profit margin was 20.60% and return on equity was 26.70% for GILD. The company reported revenue of $6.35 billion for the quarter, compared to $6.59 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -3.61 percent. For the current quarter, analysts expect GILD to generate $6.47B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/29/2023. Investors who held shares on 06/15/2023 were paid a $0.75 dividend. On an annualized basis, this represents a $3.00 dividend and a 3.83% percent yield. There was an ex-dividend date of 06/14/2023 for this dividend. In terms of dividend payout ratio, GILD is presently at 66.00%.
Gilead Sciences Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
